12:39pm ET
Health and Healthcare
Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Companies
/Healthcare
Enveric Biosciences Inc
$1.51
▲ $0.07 (+4.86%) today
Markets open · 3:16pm ET
ENVB at a Glance
Valuation
- Market cap
- $6.4M
Profitability
- Revenue (TTM)
- $35.4M
- EPS (TTM)
- $-13.01
Price
- 52-week range
- $1 – $13
- Street target
- $10.00
Earnings
- Next report
- Nov 13, 2026
Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: ENVB enveric.com
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a clinical-stage biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company leverages a differentiated drug discovery platform and a growing library of protected chemical structures to advance novel compounds designed to promote neuroplasticity without hallucinogenic effects. Its lead candidate, EB-003, is designed to selectively engage both 5-HT2A and 5-HT1B serotonin receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects suitable for outpatient use. The company's pipeline also includes the EVM301 Series of tryptamine-derived neuroplastogenic compounds and the EVM401 Series of methylone-inspired neuroplastogens. Enveric is pre-revenue, with operations centered on preclinical development and IND-enabling activities in preparation for first-in-human clinical trials. Updated
Frequently Asked Questions
What does Enveric Biosciences do?
Enveric Biosciences (NASDAQ: ENVB) is a clinical-stage biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders.
What is the ENVB stock price target?
The Wall Street consensus 12-month price target for ENVB is $10.00.